New Cancer Drug Shows Promise in Early Clinical Trials
新型癌症藥物在早期臨床試驗中展現療效潛力
In a hopeful development for oncology, researchers have unveiled encouraging phase 1 clinical trial results for a new cancer drug called setidegrasib.
針對腫瘤學而言，一項令人振奮的發展是，研究人員公布了一種名為setidegrasib的新型抗癌藥物的第一期臨床試驗結果。
Published in the New England Journal of Medicine in March 2026, this medication represents a major step forward in precision medicine.
這項研究於2026年3月發表在《新英格蘭醫學雜誌》上，代表精準醫療邁出了一大步。
Setidegrasib functions as a KRAS degrader, a cutting-edge class of drugs designed to eliminate the cancer-causing protein created by the KRAS G12D mutation.
Setidegrasib是一種KRAS降解劑，屬於尖端藥物類別，旨在消除由KRAS G12D突變所產生的致癌蛋白質。
This specific mutation is commonly found in aggressive forms of pancreatic and non-small cell lung cancer.
這種特定突變常見於侵略性胰臟癌和非小細胞肺癌。
Consequently, a global phase 3 study has been launched to confirm these initial results.
因此，一項全球性的第三期研究已經啟動，以確認這些初步結果。
